Gastric Acid, Age and GI Disorders Paper and Mind Map

The first task is the anatomy of stimulation, and the reason it is first is that everything else in the paper depends on it. Parietal cells secrete hydrogen ions through the hydrogen-potassium ATPase — the proton pump — and three separate signals drive them: gastrin released by antral G cells, histamine released by enterochromaffin-like cells acting on H2 receptors, and acetylcholine from vagal stimulation acting on muscarinic receptors. Somatostatin from D cells inhibits. Describe the three inputs converging on one pump rather than listing them, because that architecture is what makes the pharmacology in the second task make sense, and a paper that separates the physiology from the prescribing has missed the connection the assignment is built on. Name the phases too — cephalic, gastric and intestinal — since they explain why symptoms relate to meals and give the non-pharmacological advice somewhere to attach.

That convergence explains a fact worth stating explicitly: blocking the pump suppresses acid from all three pathways, while blocking the histamine receptor leaves gastrin and acetylcholine still driving secretion. It is the mechanistic reason proton pump inhibitors achieve more complete and more durable acid suppression than H2 receptor antagonists, and it is exactly the kind of link between pathophysiology and therapeutics that this assignment is assessing. Making it in the first section means the treatment section can refer back rather than starting again, which matters when three disorders and an age dimension all have to fit into the same paper. It also explains why H2 antagonists lose effect with continued use through tolerance while proton pump inhibitors do not, which is worth a sentence when you justify a first-line choice. Muscarinic antagonists act on the third pathway and are largely obsolete here, which is itself evidence for the convergence argument.

The second half of the first task asks what changes in each disorder, and the three are genuinely different mechanisms rather than three severities of one problem. Gastro-oesophageal reflux is primarily a barrier failure — transient lower oesophageal sphincter relaxation and impaired clearance — with acid as the injurious agent rather than the cause; secretion is often normal. Peptic ulcer disease is a failure of the balance between aggression and mucosal defence, most often driven by Helicobacter pylori or NSAIDs. Gastritis is inflammation of the mucosa itself, and chronic atrophic gastritis eventually *reduces* acid output by destroying the parietal cell mass. Saying that these differ in mechanism is the analytical claim the section needs. It also prevents the commonest structural error in this paper, which is describing acid three times under three headings rather than describing three different failures. Say explicitly which of the three involves normal secretion, because that is the sentence showing the distinction has been understood.

The age question is where most papers go wrong, and the error is worth naming because it is intuitive. It is commonly assumed that acid secretion falls with age and that ulcer risk therefore falls with it. The better-supported picture is that healthy ageing alone changes acid output rather less than that assumption implies; where secretion falls, it usually reflects atrophic gastritis, frequently following long-standing Helicobacter pylori infection, rather than age itself. Meanwhile the things that actually raise risk in older adults rise sharply: NSAID and aspirin exposure, polypharmacy, comorbidity, and reduced prostaglandin-mediated mucosal defence. Those are cumulative exposures rather than properties of age, which is why the distinction matters clinically: the modifiable target in an older patient is usually the exposure. Reduced renal and hepatic clearance compounds it by raising drug exposure at the same dose.

So the honest answer to how age impacts these disorders separates two things: what ageing does to the stomach, and what accumulates over a life. Complications become more common and more dangerous in older adults even where the underlying rate does not rise, because presentation is atypical — pain may be absent, and bleeding or perforation can be the first sign — and physiological reserve is lower. That reframing is more defensible than a linear acid-declines-so-risk-declines account, and it sets up the prescribing section, since it explains why the priority in an older patient is often removing an aggressor rather than suppressing acid further. Say this explicitly rather than leaving it implied, since the assignment asks how age impacts the pathophysiology and a reader should be able to see that you distinguished the two contributions rather than merging them.

Diagnosis has to be answered per disorder and per age, which is what the phrasing "based on their age" is asking for. In a younger patient with typical reflux symptoms and no alarm features, an empirical trial is reasonable and testing for Helicobacter pylori is the first investigation for suspected ulcer disease. Older age is itself commonly treated as an indication for endoscopy, alongside alarm features such as bleeding, anaemia, weight loss, dysphagia or vomiting, because the pre-test probability of malignancy is different. Saying which test you would order, in which patient, and why the threshold moves with age answers the question as asked rather than describing diagnostic options in general. Stool antigen and urea breath testing are the usual non-invasive options for Helicobacter pylori, and both require the patient to be off proton pump inhibitors beforehand — a practical detail showing the answer is about a real patient.

Prescribing needs actual agents and actual age-related cautions, since the brief says prescribe rather than discuss. Proton pump inhibitors are first line for reflux and for ulcer healing; confirmed Helicobacter pylori infection needs eradication therapy rather than acid suppression alone; an NSAID-associated ulcer needs the NSAID reconsidered, not merely covered. In older adults the specific concerns are the interactions and the long-term risks — clopidogrel and some proton pump inhibitors, hypomagnesaemia, vitamin B12 malabsorption, fracture risk, and Clostridioides difficile — which is why duration and review are part of the prescribing decision rather than an afterthought. Deprescribing is a legitimate part of the answer: a proton pump inhibitor started for a finite indication and never reviewed is among the commonest medication problems in older adults, so setting a review date is a prescribing decision rather than a caveat.

The mind map is a separate deliverable with five named elements: epidemiology, pathophysiology, clinical presentation, diagnosis and treatment, all for gastritis specifically. Two things to get right. It must be a map rather than a list, which means the branches should connect — Helicobacter pylori linking to both epidemiology and pathophysiology, atrophic change linking pathophysiology to presentation. And the brief says to include the diagnosis and treatment *you explained in your paper*, so the map has to agree with the body rather than being drawn independently. A map that contradicts the text is a visible inconsistency and an easy one for a marker to notice. Label the branches with the five element names so the marker can see all five are present without interpreting your layout. Non-pharmacological measures belong on the treatment branch too, briefly, since the assignment asks for the treatment you explained rather than the prescription alone.